Importantly, as can be seen in Figure 5, breast cancer cases showing high expression of the three receptors showed significantly better survival outcomes in HER-2-enriched (p = 0.00425) and luminal B (p = 0.0464) subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.